Income after Taxes: Earnings or losses after income tax expense but before minority interest, extraordinary items, discontinued operations, preferred dividends and accounting changes have been accounted for.
Metagenomi Therapeutics, Inc. (MGX) had Income after Taxes of $-27.48M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$-0.26M |
|
$-27.48M |
|
-- |
|
$-0.26M |
|
$28.52M |
|
$-28.77M |
|
$1.29M |
|
$-27.48M |
|
$-27.48M |
|
|
Income after Taxes |
$-27.48M |
$-27.48M |
|
$-27.48M |
|
$-27.48M |
|
$-28.77M |
|
$-27.07M |
|
37.66M |
|
37.66M |
|
$-0.73 |
|
$-0.73 |
|
| Balance Sheet Financials | |
$124.47M |
|
$9.90M |
|
$49.23M |
|
$173.70M |
|
$27.63M |
|
-- |
|
$33.50M |
|
$61.13M |
|
$112.57M |
|
$112.57M |
|
$112.57M |
|
37.78M |
|
| Cash Flow Statement Financials | |
$-40.69M |
|
$37.15M |
|
$0.04M |
|
$46.91M |
|
$43.42M |
|
$-3.49M |
|
$4.82M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.50 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
11195.72% |
|
11195.72% |
|
-- |
|
10693.39% |
|
10693.39% |
|
$-40.84M |
|
-- |
|
-- |
|
-- |
|
-0.00 |
|
-- |
|
-- |
|
-- |
|
-24.41% |
|
-24.41% |
|
-15.82% |
|
-24.41% |
|
$2.98 |
|
$-1.08 |
|
$-1.08 |
|